Clinical Trial Update: Remibrutinib in Real-world Clinical Practice - a US Sub-study

View source ↗

Summary

A US sub-study of real-world clinical practice evaluating remibrutinib for chronic spontaneous urticaria is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• Remibrutinib (remibrutinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Spontaneous Urticaria | Status: RECRUITING